Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 3/20 | 0.49 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.49 |
| ▸ | CPT1A | P50416 | 10/20 | 0.48 |
| ▸ | CPT2 | P23786 | 5/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 7/20 | 0.47 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19385273 | 1.00 | HCRTR1 (0.49) | HCRTR1HCRTR2CPT1ACPT2USP30 | |
| SCHEMBL19400840 | 0.86 | USP30 (0.50) | HCRTR1HCRTR2CPT1ACPT2USP30 | |
| SCHEMBL28918061 | 0.86 | USP30 (0.50) | HCRTR1HCRTR2CPT1ACPT2USP30 | |
| SCHEMBL22555714 | 0.77 | USP30 (0.76) | HCRTR1HCRTR2CPT1ACPT2USP30 | |
| SCHEMBL22555716 | 0.77 | USP30 (0.76) | HCRTR1HCRTR2CPT1ACPT2USP30 | |
| SCHEMBL17148989 | 0.75 | CNR2 (0.47) | USP30 | |
| SCHEMBL3554843 | 0.71 | CPT1A (0.74) | CPT1ACPT2CPT1B | |
| SCHEMBL3554829 | 0.71 | CPT1A (0.74) | CPT1ACPT2CPT1B | |
| SCHEMBL19385314 | 0.71 | USP30 (0.52) | HCRTR1HCRTR2CPT1ACPT2USP30 | |
| SCHEMBL19400904 | 0.70 | USP30 (0.61) | HCRTR1HCRTR2CPT1ACPT2USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11945797-B2 | 1-cyano-pyrrolidine derivatives as dub inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2024-04-02 | — | — | US | disclosed |
| US-20220177451-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2022-06-09 | — | — | US | disclosed |
| US-11352339-B2 | 1-cyano-pyrrolidine derivatives as DUB inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2022-06-07 | — | — | US | disclosed |
| EP-3433246-B1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DBU INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2022-05-04 | — | — | EP | disclosed |
| US-20200331888-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2020-10-22 | — | — | US | disclosed |
| EP-3433246-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DBU INHIBITORS | Mission Therapeutics Limited (GB) | 2019-01-30 | — | — | EP | disclosed |
| WO-2017163078-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DBU INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2017-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352339-B2 | 1-cyano-pyrrolidine derivatives as DUB inhibitors | USP30, USP28, USP1 | HCRTR1 1703/4885HCRTR2 3123/4885CPT1A 2466/4885 |
| US-20220177451-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS | USP30, USP28, USP1 | HCRTR1 1703/4885HCRTR2 3123/4885CPT1A 2466/4885 |
| US-11945797-B2 | 1-cyano-pyrrolidine derivatives as dub inhibitors | USP30, USP28, USP1 | HCRTR1 1703/4885HCRTR2 3123/4885CPT1A 2466/4885 |
| US-20200331888-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS | USP30, USP28, USP1 | HCRTR1 1703/4885HCRTR2 3123/4885CPT1A 2466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.